EUVIMEDEUVIMED entdecken
Crossref

Lung-only metastatic pancreatic cancer: Differences in patients ‘characteristics, molecular profile and survival

Alice Boilève, Léa Mercier, Baptiste Bonnet, Anthony Tarabay, Sarah Blanchet-Deverly, Antoine Hollebecque, Cristina Smolenschi, Marine Valéry, Matthieu Delaye, Thomas Pudlarz, Alina Fuerea, Valérie Boige und 6 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2026.116227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Alice Boilève und 17 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Université Paris Saclay, Villejuif 94805, France; Gustave Roussy, INSER…. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Lung Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: French National Research Agency.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: A better prognosis is suggested for lung-only metastases patients with pancreatic ductal adenocarcinoma (PDAC), yet biological/clinical underpinnings of organotropism in PDAC remain unclear. Study objective was to compare PDAC patients depending on their metastatic site with a special focus on "lung-only" metastases patients. METHODS: A retrospective analysis included all patients with metastatic PDAC between 2010 and 2022 in an academic-center. Lung-only patients were defined as patients with only lung metastases at diagnosis of metastases. RESULTS: Among 1012 patients, 109 (11 %) presented lung-only metastases, 506 patients (50 %) liver-only, 94 (9 %) peritoneal-only and 303 (30 %) other or multiple sites. Compared with others, lung-only patients were more frequently female (63 % vs. 46 %), older at metastatic diagnosis (median 66 vs. 63 years, p = 0.01), and less likely to have synchronous metastases (42 % vs. 69 %, p < 0.001). ctDNA detection was lower in the lung-only group with less KRAS mutations and TP53 mutations detected with liquid biopsy (but no difference was observed using tumor tissue). Median OS was higher in the lung-only group with 28.7 months (95 %CI [23.3-38.6]) vs 13.5 months (95 %CI [12.4-14.6]) for liver-only group, 11.5 months (95 %CI [9.6-16.9]) for peritoneal-only group and 11.3 months (95 %CI [10.0-13.8]) for other patients (p < 0.0001). Among lung-only patients, local treatments (n = 15) had a positive prognostic impact. CONCLUSIONS: Patients with lung-only metastases had a better OS than others, were more often women, and harbored less KRAS mutations. Our results argue in favor of PDAC with specific characteristics, especially a better prognosis, possibly further enhanced by the possibility to perform local treatments, and less detection of ctDNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsLung NeoplasmsCarcinoma, Pancreatic DuctalHumansFemaleMaleMiddle AgedAgedRetrospective StudiesMutationPrognosisAged, 80 and overProto-Oncogene Proteins p21(ras)AdultPeritoneal NeoplasmsBiomarkers, TumorLiver Neoplasms

Stichwörter der Autor:innen

Locoregional treatmentsLung metastasesOligometastaticPancreatic adenocarcinoma

Substanzen

Proto-Oncogene Proteins p21(ras)KRAS protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Université Paris Saclay, Villejuif 94805, France; Gustave Roussy, INSERM U1279, Villejuif 94805, France. Electronic address: boileve@gustaver…
  • Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France.
  • Gustave Roussy, Département d'imagerie thérapeutique, Villejuif 94805, France.
  • Gustave Roussy, Département de Médecine Oncologique, Villejuif 94805, France; Gustave Roussy, Drug Development Department (DITEP), Villejuif, France.
  • Gustave Roussy, Département de radiothérapie, Villejuif 94805, France.
  • Gustave Roussy, Département de chirurgie, Villejuif 94805, France.

Förderung

  • French National Research Agency

Zitieren

APA

Boilève, A., Mercier, L., Bonnet, B., Tarabay, A., Blanchet-Deverly, S., Hollebecque, A., Smolenschi, C., Valéry, M., Delaye, M., Pudlarz, T., Fuerea, A., Boige, V., Durand-Labrunie, J., Gelli, M., Beunon, P., Barbe, R., Lambert, A., & Ducreux, M. (2026). Lung-only metastatic pancreatic cancer: Differences in patients ‘characteristics, molecular profile and survival. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2026.116227

Vancouver

Boilève A, Mercier L, Bonnet B, Tarabay A, Blanchet-Deverly S, Hollebecque A, et al. Lung-only metastatic pancreatic cancer: Differences in patients ‘characteristics, molecular profile and survival. European Journal of Cancer. 2026. doi:10.1016/j.ejca.2026.116227

BibTeX
@article{Boilve2026,
  author = {Boilève, Alice and Mercier, Léa and Bonnet, Baptiste and Tarabay, Anthony and Blanchet-Deverly, Sarah and Hollebecque, Antoine and Smolenschi, Cristina and Valéry, Marine and Delaye, Matthieu and Pudlarz, Thomas and Fuerea, Alina and Boige, Valérie and Durand-Labrunie, Jérome and Gelli, Maximiliano and Beunon, Paul and Barbe, Rémy and Lambert, Aurélien and Ducreux, Michel},
  title = {Lung-only metastatic pancreatic cancer: Differences in patients ‘characteristics, molecular profile and survival},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2026.116227}
}
Kostenlos starten →